DelSiTech™Silica is an advanced delivery technology for parenteral and local administration of injectable depot and implant dosage forms. The proprietary technology is based on silica (SiO2) matrix into which the active ingredient is embedded. The matrix can be designed to biodegrade at the required rate to assure a tightly controlled release of the active substance, providing a better therapeutic effect in situ and causing lower systemic and local adverse effects than alternative delivery systems.
The technology was developed at the University of Turku and Åbo Akademi University by the Biomaterial Research Group in Turku, Finland and is fully owned and patented by DelSiTech.
Watch an animated video on DelSiTech drug delivery technology